See more : Manoj Vaibhav Gems ‘N’ Jewellers Limited (MVGJL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Odonate Therapeutics, Inc. (ODT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odonate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Ameren Illinois Company (AILIM) Income Statement Analysis – Financial Results
- Zhejiang Changsheng Sliding Bearings Co., Ltd. (300718.SZ) Income Statement Analysis – Financial Results
- LS FAANG+ ETP (FAAN.L) Income Statement Analysis – Financial Results
- Bajel Projects Limited (BAJEL.BO) Income Statement Analysis – Financial Results
- Bahvest Resources Berhad (0098.KL) Income Statement Analysis – Financial Results
Odonate Therapeutics, Inc. (ODT)
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 117.04M | 104.03M | 79.95M | 27.90M | 2.62M | 0.00 |
| General & Administrative | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -316.00K |
| Operating Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | -158.00K |
| Cost & Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
| Interest Income | 0.00 | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 445.00K | 381.00K | 350.00K | 20.00K | 22.82K | 0.00 |
| EBITDA | -125.91M | -111.44M | -88.61M | -32.72M | -3.09M | -158.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -127.43M | -114.93M | -90.76M | -32.74M | -3.09M | -158.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
| Net Income | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| EPS Diluted | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
| Weighted Avg Shares Out | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
| Weighted Avg Shares Out (Dil) | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 15, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therapeutics, Inc. ("Odonate" or "the Company") (NASDAQ: ODT) for violations of...
FINAL DEADLINE NOTICE: Rosen, Global Investor Counsel, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT
New York, New York--(Newsfile Corp. - November 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the...
ODT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Odonate Therapeutics, Inc. Shareholders With Losses Exceeding $50K of Class Action and Lead Plaintiff Deadline: November 16, 2020
New York, New York--(Newsfile Corp. - November 13, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odonate" or the "Company") (NASDAQ: ODT) and certain of its officers,...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Odonate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 16, 2020 - ODT
New York, New York--(Newsfile Corp. - November 12, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Odonate Therapeutics, Inc. ("Odonate") (NASDAQ: ODT) between December...
ODT FINAL DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Reminds Odonate Therapeutics, Inc. Investors of Important Monday Deadline in Securities Class Action - ODT
NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and August 21, 2020, inclusive (the "Class Period"), of...
MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therapeutics, Inc. ("Odonate" or "the Company") (NASDAQ: ODT) for violations of...
MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Odonate Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 10, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odonate Therapeutics, Inc. (NASDAQ: ODT) ("Odonate" or "the Company") for violations of...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Odonate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 16, 2020 - ODT
New York, New York--(Newsfile Corp. - November 9, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Odonate Therapeutics, Inc. ("Odonate") (NASDAQ: ODT) between December...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Odonate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 16, 2020 - ODT
New York, New York--(Newsfile Corp. - November 6, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Odonate Therapeutics, Inc. (NASDAQ: ODT)("Odonate") between December 7,...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Odonate Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 16, 2020 - ODT
New York, New York--(Newsfile Corp. - November 4, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Odonate Therapeutics, Inc. ("Odonate") (NASDAQ: ODT) between December...
Source: https://incomestatements.info
Category: Stock Reports